Human B7-H4 Protein
Catalog No: B7H4-HP002
- Species
- Human
- Expression System
- HEK293
- Tag
- His
- Activity
- Activity verified
Product overview
Recombinant Human B7-H4 Protein is expressed in HEK293 cells with a His tag at the C-terminus. It contains amino acid residues Phe29-Ala258 (UniProt accession: Q7Z7D3-1).
Product Details
- Molecular Aliases
- B7H4; B7-H4; B7S1; B7h.5; B7x; FLJ22418; VTCN1; PRO1291
- Protein Length
- Phe29-Ala258
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 26.92 kDa. Due to glycosylation, the protein migrates to 50-65 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 0.1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human B7-H4 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human B7-H4 is greater than 95% as determined by SEC-HPLC.
Immobilized Human B7-H4, His Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Anti-B7-H4 Antibody, hFc Tag with the EC50 of 8.6ng/ml determined by ELISA. (QC Test)
Loaded Anti-B7-H4 Antibody, hFc Tag on ProA-Biosensor can bind Human B7-H4, His Tag with an affinity constant of 8.62 nM as determined in BLI assay.
Background
B7-H4, also known as B7x and B7S1, is a 50-80 kDa glycosylated member of the B7 family of immunomodulatory proteins. B7-H4 is up-regulated in several carcinomas in correlation with tumor progression and metastasis. A soluble form of B7-H4 is elevated in the serum of ovarian cancer, renal cell carcinoma, and rheumatoid arthritis patients, also in correlation with advanced disease status.
References
- Smith J B, Caitlin S, Powell D J. B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look[J]. Gynecologic Oncology, 2014, 134(1):181-189. Note: HPLC results always come from liquid protein, due to absorption peak interference of trehalose in lyophilized powder.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.